アスタキサンチン

Two principal Japanese producers are commonly referenced: Fuji Chemical Industry (富士化学工業, AstaReal® brand) — pioneering closed-system Haematococcus pluvialis cultivation and one of the largest natural astaxanthin producers globally — and ENEOS (formerly JX Nippon Oil & Energy / J-OIL MILLS in some product lines), with the Panaferd® brand from Paracoccus carotinifaciens for animal feed pigmentation and human-supplement variants. AstaReal® is the most-cited branded source in Japanese FFC notifications.

Industry-typical MOQ is 1–10 kg for oil-based concentrates (5–10% astaxanthin in oil) and 100 g–1 kg for spray-dried encapsulated powders (typically 1.5–3% astaxanthin), with 6–12 week lead times. Microalgae cultivation cycles and the careful downstream processing required to preserve oxidation-sensitive astaxanthin are the principal drivers of lead time. Branded materials (AstaReal®, Panaferd®) come with documentation packages supporting EU Novel Food, Japan FFC, and US GRAS positioning.

Standard COA: total astaxanthin (HPLC), free-form vs. esterified ratio, stereoisomer profile (3S,3'S preferred for natural Haematococcus), peroxide value, oxidation-stability data, microbiological limits, heavy metals (with attention to mercury for any marine sources), and source-organism documentation. Certifications: kosher, halal, non-GMO, organic (where applicable), allergen-free statement. Stability data are critical: request real-time and accelerated-condition studies in the proposed packaging configuration.

EFSA's ADI of 0.034 mg/kg body weight/day (approximately 2 mg/day for a 60 kg adult) means that supplement products targeting EU markets typically need to dose at or below 2 mg/day per serving — significantly below the 4–12 mg/day common in Japanese and US products. Manufacturers building dual-region supplement lines often run two SKUs (EU-compliant lower-dose and Japan-FFC higher-dose) or design label warnings for vulnerable populations. Confirm with regulatory counsel for each market.